Wednesday's IBD 50 Stocks To Watch pick is fintech Dave (DAVE), which is rapidly approaching a buy point from a rare chart pattern, making it one of the best stocks to buy and watch right now.
Dave is a digital financial services company that develops banking applications. Its app launched in 2017 to help Americans take control of their finances, according to the company.
↑ XDave's CashAI is a proprietary artificial intelligence underwriting model that analyzes cash flow, not credit scores, to determine members' eligibility for loans every time they need more money. Highly dynamic and personalized, CashAI analyzes more than 180 different data points, including members' income, irregular employment, bank balance, spending patterns and their history with the Dave app.
Per the company, "This transaction access gives us what we believe is an unparalleled view into customer finances not found with lagging and less comprehensive FICO indicators and enables us to offer credit to our members within minutes of joining, helping them to avoid costly overdraft fees and payday loans found elsewhere."
In its latest quarterly results, reported on Nov. 12, the company swung to a profit of $1.51 per share from a loss of 47 cents a share in the year-ago period. Sales jumped 41% to $92.5 million. That marked an acceleration in revenue from gains of 16%, 23%, 25% and 31% the previous quarters.
"We once again exceeded growth and profitability expectations in the third quarter," said Chief Executive Jason Wilk in the press release.
Wilk continued, "Our fourth consecutive quarter of accelerating year-over-year revenue growth resulted from double-digit increases in both ARPU (average revenue per user) and monthly transacting members to quarterly records for both metrics."
For the full year, Wall Street analysts expect the company to earn $4.64 per share. In 2025. EPS is seen growing 8% to $5.02 a share, per IBD MarketSurge.
This Industry Group — And 4 IPOs — Polish 20 'Perfect' Gems
The stock formed a short-stroke pattern, a formation that is quite unusual. It forms over just two weeks. The first week is marked by a strong advance — 10% to 20% or even more — and usually coincides with or comes shortly after a breakout from a solid base.
The second week shows tight trading. The difference between the stock's weekly high and low is typically just a few percentage points, without hitting a new high.
On Nov. 13, Dave stock gapped up 44%, hitting a 52-week high that resulted in a 51% weekly gain. Last week, shares rose less than 8%. That places the buy point for the short stroke at 94.96.
Bullishly, the stock's relative strength line hit a new high during the recent powerful advance. That confirms shares are beating the performance of the S&P 500.
Amid powerful gains in recent years, Dave stock boasts a 97 out of a best-possible 99 Composite Rating from Investor's Business Daily, according to IBD Stock Checkup.
Cracks Emerge In Nvidia's AI Armor. What's An Investor To Do?
Three recent IBD 50 Growth Stocks To Watch picks are among the best stocks to buy and watch.
Company | Symbol | Buy point | Type of base |
---|---|---|---|
Atour Lifestyle | (ATAT) | 29.15 | Consolidation |
GeneDx | (NVDA) | 89.11 | Consolidation |
Rhythm Pharmaceuticals | (RYTM) | 55.64 | Consolidation |
Follow Scott Lehtonen on X at @IBD_SLehtonen for more on the best stocks to buy and watch and the Dow Jones Industrial Average.
YOU MAY ALSO LIKE:
IBD's New Exposure Levels
Top Growth Stocks To Buy And Watch
Learn How To Time The Market With IBD's ETF Market Strategy
Find The Best Long-Term Investments With IBD Long-Term Leaders
Spot Buy Points And Sell Signals With MarketSurge Pattern Recognition
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。